| |
| |
|
| Insider
Information: |
Stahl Neil |
| Relationship: |
EVP Research and Devel... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
50,999 |
|
|
Indirect Shares
|
10,439 |
|
|
| Direct
Value |
$49,464,440 |
|
|
|
Indirect Value
|
$10,124,890 |
|
|
| Total
Shares |
61,438 |
|
|
| Total
Value |
$59,589,331 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 57.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regeneron Pharmaceuticals Inc |
REGN |
EVP Research and Devel... |
2024-02-26 |
50,999 |
2024-02-26 |
10,439 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
140 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-02-12 |
4 |
D |
$402.34 |
$5,923,249 |
D/D |
(14,722) |
21,658 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2018-05-23 |
4 |
D |
$293.68 |
$4,501,821 |
D/D |
(15,329) |
43,380 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
officerTitle |
• – – |
2006-02-03 |
4 |
D |
$16.40 |
$252,576 |
D/D |
(15,401) |
11,726 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
officerTitle |
• – – |
2006-02-03 |
4 |
AS |
$15.86 |
$253,760 |
D/D |
(16,000) |
3,127 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-11-18 |
4 |
OE |
$115.29 |
$1,931,915 |
D/D |
16,757 |
30,284 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-08-29 |
4 |
S |
$144.92 |
$2,460,647 |
D/D |
(16,884) |
59,121 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-11-30 |
4 |
S |
$181.01 |
$3,110,114 |
D/D |
(17,182) |
41,939 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-05-17 |
4 |
S |
$518.63 |
$9,101,460 |
D/D |
(17,521) |
24,280 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-11-06 |
4 |
S |
$562.37 |
$11,260,068 |
D/D |
(20,000) |
44,130 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-21 |
4 |
OE |
$30.63 |
$612,600 |
D/D |
20,000 |
43,950 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2017-06-14 |
4 |
OE |
$21.25 |
$431,269 |
D/D |
20,295 |
44,245 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-08-06 |
4 |
D |
$336.11 |
$6,894,624 |
D/D |
(20,513) |
28,014 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-02-15 |
4 |
S |
$107.79 |
$2,273,036 |
D/D |
(21,082) |
59,121 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-11-09 |
4 |
S |
$558.37 |
$12,377,559 |
D/D |
(22,101) |
22,029 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-02-13 |
4 |
S |
$316.55 |
$7,209,136 |
D/D |
(22,612) |
24,391 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2024-02-02 |
4 |
D |
$956.65 |
$21,728,391 |
D/D |
(22,713) |
60,056 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2013-05-13 |
4 |
S |
$276.71 |
$6,378,806 |
D/D |
(23,038) |
48,988 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-08-28 |
4 |
D |
$145.70 |
$3,368,001 |
D/D |
(23,116) |
76,005 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-08-05 |
4 |
S |
$606.78 |
$14,569,134 |
D/D |
(23,782) |
52,795 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-11-21 |
4 |
S |
$173.80 |
$4,245,442 |
D/D |
(24,357) |
59,121 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2007-04-20 |
4 |
OE |
$8.77 |
$219,250 |
D/D |
25,000 |
29,297 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2008-09-29 |
4 |
OE |
$8.77 |
$219,250 |
D/D |
25,000 |
25,350 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-02-12 |
4 |
OE |
$52.03 |
$1,300,750 |
D/D |
25,000 |
36,380 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-02-26 |
4 |
OE |
$52.03 |
$1,300,750 |
D/D |
25,000 |
36,380 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2018-05-23 |
4 |
OE |
$30.63 |
$818,924 |
D/D |
26,736 |
58,709 |
0 |
- |
|
140 Records found
|
|
Page 4 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
